US 11,944,647 B2
Articles of manufacture and methods for treatment using adoptive cell therapy
Tina Albertson, Seattle, WA (US); Brian Christin, Seattle, WA (US); Jacob Randolph Garcia, Seattle, WA (US); Christopher Glen Ramsborg, Seattle, WA (US); Claire L. Sutherland, Seattle, WA (US); Clinton Weber, Seattle, WA (US); Rachel K. Yost, Seattle, WA (US); Mark J. Gilbert, Seattle, WA (US); and He Li, Seattle, WA (US)
Assigned to Juno Therapeutics, Inc., Seattle, WA (US)
Filed by Juno Therapeutics, Inc., Seattle, WA (US)
Filed on Jun. 22, 2022, as Appl. No. 17/846,868.
Application 17/846,868 is a continuation of application No. 16/616,938, granted, now 11,413,310, previously published as PCT/US2018/035755, filed on Jun. 1, 2018.
Claims priority of provisional application 62/614,957, filed on Jan. 8, 2018.
Claims priority of provisional application 62/596,764, filed on Dec. 8, 2017.
Claims priority of provisional application 62/593,871, filed on Dec. 1, 2017.
Claims priority of provisional application 62/580,425, filed on Nov. 1, 2017.
Claims priority of provisional application 62/549,938, filed on Aug. 24, 2017.
Claims priority of provisional application 62/527,000, filed on Jun. 29, 2017.
Claims priority of provisional application 62/521,366, filed on Jun. 16, 2017.
Claims priority of provisional application 62/515,530, filed on Jun. 5, 2017.
Claims priority of provisional application 62/514,774, filed on Jun. 2, 2017.
Prior Publication US 2023/0149458 A1, May 18, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/17 (2015.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/73 (2006.01)
CPC A61K 35/17 (2013.01) [A61P 35/00 (2018.01); C07K 14/70514 (2013.01); C07K 14/70517 (2013.01)] 20 Claims
 
1. A method of treating a subject having small lymphocytic lymphoma (SLL), the method comprising administering to the subject a dose of T cells comprising T cells expressing a chimeric antigen receptor (CAR) that specifically binds to CD19, the dose of T cells comprising a ratio of CD4+ cells expressing the CAR to CD8+ cells expressing the CAR of between at or about 5:1 and at or about 1:5, wherein;
administering the dose of T cells comprises administering a plurality of separate compositions, the plurality of separate compositions comprising a first composition comprising one of the CD4+ T cells and the CD8+ T cells and a second composition comprising the other of the CD4+ T cells and the CD8+ T cells;
the subject has relapsed following remission after treatment with, or become refractory to, one or more prior therapies; and
the CAR comprises an scFv specific for CD19, a transmembrane domain, a cytoplasmic signaling domain derived from a costimulatory molecule, a cytoplasmic signaling domain that comprises a CD3zeta signaling domain, and a spacer between the transmembrane domain and the scFv.